Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

About

Brief Summary

This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

Study Type

Observational

Phase

N/A

Eligibility

Gender

All

Healthy Volunteers

Minimum Age

N/A

Maximum Age

99 Years

Inclusion Criteria:

ELIGIBILITY CRITERIA - CASES
Diagnosis of primary cancer at age 21 or younger, irrespective of current age
No prior history of allogeneic (non-autologous) hematopoietic cell transplant
Development of one of the following key adverse events at any time following initiation of cancer therapy:
- Cardiac dysfunction; please note: case enrollment has been closed due to achievement of target accrual
- Ischemic stroke (IS)
- Subsequent malignant neoplasm (SMN)
- Avascular necrosis (AVN); please note: case enrollment has been closed due to achievement of target accrual
Submission of a blood specimen (or in certain cases a saliva specimen) to the Coordinating Center at the University of Alabama at Birmingham as per the requirements; please note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's white blood cell (WBC) is > 2,000
Written informed consent from the patient and/or the patient's legally authorized guardian
In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; please note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required
ELIGIBILITY CRITERIA - CONTROLS
CONTROL: Diagnosis of primary cancer at age 21 or younger, irrespective of current age
CONTROLS: No prior history of allogeneic (non-autologous) hematopoietic cell transplant
CONTROLS: No clinical evidence of any of the following key adverse events:
- Cardiac dysfunction (CD); please note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's WBC is > 2,000
- Ischemic stroke (IS)
- Avascular necrosis (AVN)
- Subsequent malignant neoplasm (SMN)
CONTROLS: Submission of a blood specimen (or in certain cases a saliva specimen) to the Coordinating Center Laboratory at the University of Alabama at Birmingham as per the requirements
CONTROLS: Written informed consent from the patient and/or the patient's legally authorized guardian
CONTROLS: In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; please note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required

Join this Trial